Teva Pharmaceutical Industries Limited (NYSE:TEVA) declared a quarterly dividend on Thursday, November 2nd, RTT News reports. Shareholders of record on Tuesday, November 28th will be given a dividend of 0.085 per share on Tuesday, December 12th. This represents a $0.34 annualized dividend and a yield of 2.55%. The ex-dividend date is Monday, November 27th.

Teva Pharmaceutical Industries Limited has raised its dividend payment by an average of 2.1% annually over the last three years. Teva Pharmaceutical Industries Limited has a dividend payout ratio of 7.6% meaning its dividend is sufficiently covered by earnings. Research analysts expect Teva Pharmaceutical Industries Limited to earn $2.84 per share next year, which means the company should continue to be able to cover its $0.29 annual dividend with an expected future payout ratio of 10.2%.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at $13.33 on Wednesday. The stock has a market cap of $13,289.28, a P/E ratio of 3.02 and a beta of 0.52. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries Limited has a 12-month low of $10.85 and a 12-month high of $38.69.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-to-go-ex-dividend-on-november-27th/1719430.html.

Several research firms have weighed in on TEVA. BidaskClub lowered shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Citigroup Inc. downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $32.00 to $19.00 in a report on Wednesday, August 16th. Credit Suisse Group reissued an “outperform” rating and issued a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. lowered Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and set a $41.00 price objective for the company. in a research note on Thursday, August 3rd. Seven analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $21.88.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Dividend History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.